Results 11 to 20 of about 10,028,727 (294)
, 2018 Vitamin K antagonists are widely used for prevention of thrombosis in patients at high risk. Dosage requirements differ greatly among individuals, and interactions are observed with other pharmaceuticals or dietary compounds, necessitating frequent ...
Jane Skov, Jørgen Jespersen
core +3 more sources
Vitamin K metabolism in a patient resistant to vitamin K antagonists.
Haemostasis, 1997 We investigated various pharmacokinetic and pharmacodynamic parameters in a 63-year-old man, resistant to warfarin, fluindione, acenocoumarol and phenprocoumon.
Samama, M.M. +17 more
core +4 more sources
Pharmacogenomics of vitamin K antagonists
Revista medica de Chile, 2021 There is an important interindividual variability in dose requirement for coumarinic anticoagulants, which could be explained by genetic and non-genetic factors.
Letelier, Pablo +6 more
core +2 more sources
Vitamin K antagonist use and renal function in pre-dialysis patients
Clinical Epidemiology, 2018 Pauline WM Voskamp,1 Friedo W Dekker,1 Maarten B Rookmaaker,2 Marianne C Verhaar,2 Willem Jan W Bos,3 Merel van Diepen,1 Gurbey Ocak2 1Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; 2Department of ...
Voskamp PWM +6 more
doaj +1 more source
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation [PDF]
TH Open, 2018 Background Vitamin K antagonists (VKAs) are associated with coronary artery calcification in low-risk populations, but their effect on calcification of large arteries remains uncertain.
Frederique E. C. M. Peeters +11 more
doaj +3 more sources
Quality of Anticoagulation With Vitamin K Antagonists [PDF]
Clinical Cardiology, 2015 ABSTRACTBackgroundVitamin K antagonists (VKA) have a narrow therapeutic range, and literature analysis reveals poor quality of anticoagulation control. We sought to assess the prevalence of poor anticoagulant control in patients under VKA treatment in the prevention of stroke for atrial fibrillation (AF).HypothesisControl of anticoagulation with VKA is
Bertomeu-González, Vicente +9 more
openaire +4 more sources
Urgent reversal of vitamin K antagonists [PDF]
BMJ, 2018 ### What you need to know A 78 year old man is brought to the emergency department after collapsing. He is drowsy with signs of a left hemiparesis. Computed tomography of the brain shows an intracranial bleed. He has a history of atrial fibrillation, and he has been taking warfarin (INR target 2-3) for several years.
Beverley J, Hunt, Marcel, Levi
openaire +5 more sources
NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions
Global Heart, 2020 The introduction of non-vitamin K antagonists oral anticoagulants, a class of medicines which includes dabigatran, apixaban, edoxaban and rivaroxaban, has resulted in improvements in the safety and efficacy of non valvular atrial fibrillation treatment ...
Mariachiara Di Cesare +8 more
doaj +1 more source
Атеротромбоз, 2017 The article presents the experience in management of occlusive deep vein thrombosis with enoxaparin sodium in outpatient settings. The study included two groups of patients: the patients of the first group received unfractionated heparin for 10-14 days ...
A. M. ZUDIN, A. G. FAIBUSHEVICH
doaj +1 more source
Comparing Clinical Outcomes of Vitamin K Antagonists vs Non-Vitamin K Antagonists in Anticoagulant Therapy for Mesenteric Venous Thrombosis [PDF]
Journal of Vascular Surgery: Venous and Lymphatic DisordersWoo-Sung Yun, Seung Huh, Hyung-Kee Kim
exaly +2 more sources